IPL 576092

Drug Profile

IPL 576092

Alternative Names: 4011; HMR 4011A; IPL 576,092

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma; Atopic dermatitis; Ocular inflammation

Most Recent Events

  • 07 Feb 2017 Discontinued - Phase-I for Asthma in Canada (Inhalation)
  • 07 Feb 2017 Discontinued - Phase-I/II for Allergic rhinitis in Canada (Intranasal)
  • 07 Feb 2017 Discontinued - Phase-II for Asthma in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top